- Trial phase
- Approved
- Time to market
- Already approved and on the market (US approval March 2021; EU approval also granted).
- Why 4/10
- Abecma is already approved and commercialized with no pending regulatory decision or pivotal readout in the next ~12 months. For a large diversified pharma like BMY (~$50B revenue), Abecma is a small part of the portfolio. Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5, and Abecma's modest revenue contribution places it at a 4.
The next relevant event for the BCMA CAR-T competitive landscape is the FDA PDUFA date of December 23, 2026 for Gilead/Arcellx's anito-cel, which would introduce a third BCMA-directed CAR-T into the US multiple myeloma market. For BMY investors, Abecma's trajectory is more likely to be influenced by broader company dynamics (patent cliff on Eliquis/Opdivo, pipeline readouts for other assets) than by this single drug, which is an approved, mature product facing competitive erosion.
Price Chart
Executive Summary
Abecma (idecabtagene vicleucel) is a BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma, approved by the FDA in 2021 and expanded to earlier treatment lines in 2024 based on the Phase 3 KarMMa-3 trial. It is fully owned and commercialized by Bristol Myers Squibb (BMY) after its 2025 acquisition of former partner 2seventy bio. While the label expansion and REMS removal are positive, the drug faces fierce competition from J&J/Legend's Carvykti, which is taking significant market share. Abecma generated ~$242M in US sales in 2024, a modest figure within BMY's overall ~$50B revenue base. No near-term binary catalyst is expected for this mature, approved asset.
How It Works
A personalized cell therapy (CAR-T) where a patient's own T cells are genetically reprogrammed to recognize and kill cancer cells that carry a protein called BCMA, which is found on multiple myeloma cells. The modified cells are infused back into the patient as a one-time treatment.
Trial Status
Abecma was initially FDA-approved in March 2021 for relapsed/refractory multiple myeloma after 4+ prior lines of therapy. The label was expanded in April 2024 to include patients after 2+ prior lines, based on the Phase 3 KarMMa-3 trial which showed a median progression-free survival of 13.3 months vs 4.4 months for standard regimens, a 51% reduction in the risk of disease progression or death. Updated KarMMa-3 results with ~31 months of follow-up were presented at the 2026 Tandem Meetings. The FDA removed the REMS program requirement for Abecma in June 2025 as part of label streamlining.
The Two-Sided Case
Upcoming Catalysts
- No pending FDA decision or pivotal readout scheduled for Abecma specifically in the next ~12 months. The competitive landscape shifts on December 23, 2026, when the FDA decides on Gilead/Arcellx's anito-cel, a new BCMA CAR-T competitor.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report